Monoclonal immunoglobulins and tbe measurement of inorganic pbosphate in serum
I read with interest the recent paper of Bowles et al.I on pseudohyperphosphataemia in patients with monoclonal paraproteins, and would fully endorse their conclusions on the clinical implications of such findings.? A recent review of the scattered previous reports of monoclonal paraprotein-associated pseudohyperphosphataernia confirmed the lack of any apparent association with particular immunoglobulin type or subclass.' The observation that paraprotein concentration is not related to presence or absence of interf'erence' is consistent with the report of Morin and Prox that addition of up to 50 giL of exogenous globulin did not interfere with the phosphomolybdate assay." It should be recalled, however, that mechanisms other than protein precipitation may be responsible for some cases of pseudohyperphosphataemia: some authors have not observed turbidity in the reaction mixturc.! and phosphate binding by the myeloma protein has been recorded in one case."
The phenomenon of paraprotein interference due to precipitation of monoclonal protein may be generally applicable to spectrophotometric assays. Such interference has been noted in spectrophotometric assays of chloride ion concentration (which influences measurement of anion gap),? glucose," and haemoglobm.v-" The fact that the prevalence of pseudohyperphosphataemia when looked for systematically is very much higher' than indicated by the paucity of case reports in the literature' suggests that a similar evaluation of other spectrophotometric assays may reveal paraprotein interference to be more common than currently thought. The findings of Bowles and colleagues may thus have an applicability wider than just inorganic phosphate measurements. ANDREW 
Measurement of 5-HIAA in urine
We would like to comment on the publication of Deacon, I who reviewed clinical chemical aspects of urinary 5-hydroxyindoleacetic acid (5-HIAA) and stated that 'the current consensus is that urinary 5-HIAA serves as the most consistent biochemical marker of the carcinoid syndrome but that there may be a role for the estimation of other indoles'. In our opinion, this statement does not give proper credit to the higher sensitivity of platelet serotonin (5-HT) as a biochemical marker for diagnosis of carcinoid tumours.
It has been established that certain carcinoid tumours give rise to elevated platelet 5-HT in the presence of normal urinary 5-HlAA. 2 -4 Recently, we used existing high performance liquid chromatography/fluorometry methods to compare the sensitivities of urinary 5-HIAA and urinary, plasma and platelet 5-HT in 30 consecutive patients with histologically proven carcinoid tumours of fore-(n = 11), mid-(n = 14) and hindgut (n = 5) origin before treatment. 5 Ten patients showed no signs of 5-HT overproduction and 14 had increases of both urinary 5-HlAA and platelet 5-HT, platelet 5-HT, but not urinary 5-HIAA, was increased in six. No patient had increased urinary 5-HIAA without increased platelet 5-HT. Platelet 5-HT (urinary 5-HIAA) [urinary 5-HT] were increased in 5/11 (1111) [217] patients with foregut-, 14/14 (13/14) [10/13] with midgut and 1/5 (0/5) [2/5] with hindgut carcinoid tumours. In cases with higher tumour 5-HT secretion rates, platelet 5-HT reached a maximum and did not correlate with 5-HT secretion rate, whereas urinary 5-HlAA did. From the 14 patients who exhibited carcinoid syndrome (the clinical manifestation of carcinoid tumours) all had increased platelet 5-HT and 13 increased urinary 5-HIAA. Long-term follow up of 44 patients (including the 30 mentioned earlier) not only confirmed higher sensitivity of platelet 5-HT, but also showed that it is more consistently elevated than urinary 5-HlAA. 6 Consumption of a 5-HT (about 256/Lmol) rich diet by healthy adults does not influence platelet 5-HT, but may increase urinary 5-HIAA up to about 150 times median basal levels. 7 This data shows that platelet 5-HT has higher sensitivity for the detection of carcinoid tumours than urinary 5-HIAA, particularly those that are characterized by low 5-HT production rate. Its measurement does not necessitate avoidance of 5-HT containing foods prior to sample collection. Author's reply Kema et al. found platelet serotonin (5-HT) to be a more sensitive marker for carcinoid tumours than urinary 5-hydroxyindoleacetic acid (5-HIAA), this finding however conflicts with data published by Feldman;' In his series of 75 patients, 750/0 had raised urinary 5-HlAA, 64% had elevated platelet 5-HT, however, two patients had raised platelet 5-HT with normal urinary 5-HIAA output. Whilst some patients had minimal increases in urinary 5-HIAA, the same was true of platelet 5-HT in patients in whom 5-HIAA was normal. Both measurements yield complementary information, so that neither test alone can be relied upon to detect all 5-HTsecreting tumours. This view may well change once larger series of patients have been studied using the more specific HPLC techniques for both 5-HIAA and 5-HT. The observation of Kema et al. that urinary 5-HIAA excretion correlates with 5-HT secretion in tumours with high 5-HT secretion rates, but that platelet 5-HT reaches a maximum and does not correlate, infers that such patients' should be monitored by measurement of 5-HlAA excretion.
I agree that urinary 5-HIAA is far more susceptible to the effects of high 5-HT intake
